Evidence-Based Management of Spasticity in MS with Cannabinoids

Pharmacodynamics of Cannabinoids in Motor Control

The management of spasticity in Multiple Sclerosis (MS) represents one of the most robust clinical applications for cannabinoid-based medicines. While conventional antispasmodics often achieve symptom reduction at the cost of significant sedation or muscle weakness, the endocannabinoid system (ECS) offers a more nuanced regulatory pathway. The pathophysiology of MS involves demyelination and axonal damage, leading to an imbalance between excitatory and inhibitory neurotransmission in the spinal cord and brain.

Cannabinoids, specifically the synergy between delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in balanced ratios, modulate this hyperexcitability. THC acts as a partial agonist of CB1 receptors located on pre-synaptic glutamatergic and GABAergic terminals. This modulation helps restore the "tone" of motor neurons, potentially reducing the frequency and severity of involuntary spasms without the profound hypotonia associated with central nervous system depressants.

Evidence from Controlled Clinical Trials

The clinical validity of standardized oromucosal sprays—specifically nabiximols—is supported by a substantial body of evidence from randomized, double-blind, placebo-controlled trials. Unlike smoked cannabis, which lacks dose consistency and carries respiratory industrial risks, standardized formulations allow for precise titration and reproducible plasma levels.

Systematic reviews of these trials often highlight a "responder" phenomenon. Data suggest that a significant percentage of patients experience a reduction in spasticity scores (measured by scales like the Modified Ashworth Scale or Numerical Rating Scales) during an initial trial phase. For those who respond, the therapeutic benefit tends to be maintained over the long term without the development of significant tolerance. Furthermore, the evidence indicates secondary improvements in sleep quality and bladder dysfunction, which are frequently comorbid with spasticity in MS populations.

Dosing Strategies and Safety Profile

For the clinician, the "start low, go slow" principle is paramount, particularly in a population with potential cognitive or balance vulnerabilities. Standard protocols involve a gradual upward titration over a period of two weeks. This approach allows the patient's nervous system to acclimate to the psychoactive properties of THC while reaching a therapeutic threshold that manages motor symptoms.

The safety profile of balanced cannabinoid extracts is generally favorable compared to escalating doses of baclofen or tizanidine. Common adverse effects include dizziness, fatigue, and dry mouth, which are typically dose-dependent and transient. Crucially, the pharmaceutical-grade nature of these extracts ensures the absence of contaminants—such as heavy metals or pesticides—and provides a characterized terpene profile that may contribute to the overall therapeutic effect through the entourage effect, although further research is needed to isolate these specific interactions.

Practical Implementation in Specialist Care

Integrating cannabinoid therapy into the MS management plan requires a multidisciplinary approach. It should be considered an add-on therapy for patients who have not achieved adequate relief from first-line medications or who experience dose-limiting side effects. Monitoring should focus not only on the reduction of spasticity but also on functional outcomes: Is the patient more mobile? Has their quality of life improved?

As we move toward 2025, the clinical consensus continues to solidify around the use of standardized cannabinoid ratios as a legitimate tool in the neurological toolkit. By providing patients with pharmaceutical-grade options, we mitigate the risks associated with the illicit market and ensure that the therapeutic window is maximized through precise, evidence-based prescribing.